GB1564160A - Tethrahydronaphthalene derivatives - Google Patents

Tethrahydronaphthalene derivatives Download PDF

Info

Publication number
GB1564160A
GB1564160A GB14546/79A GB1454679A GB1564160A GB 1564160 A GB1564160 A GB 1564160A GB 14546/79 A GB14546/79 A GB 14546/79A GB 1454679 A GB1454679 A GB 1454679A GB 1564160 A GB1564160 A GB 1564160A
Authority
GB
United Kingdom
Prior art keywords
formula
tetrahydro
compound
cis
naphthalenetriol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB14546/79A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Publication of GB1564160A publication Critical patent/GB1564160A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/17Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings, e.g. cyclohexylphenol

Description

PATENT SPECIFICATION
( 21) Application No 14546/79 ( 22) Fi ( 62) Divided out of No 1564159 ( 31) Convention Application No 656769 ( 32) Filed 9 Feb 1976 in ( 33) ( 44) ( 51) ( 52) ( 72) iled 31 Dec 1976 United States of America (US)
Complete Specification published 2 April 1980
INT CL 3 C 07 D 407/12 (C 07 D 407/12 303/26 317/70) Index at acceptance C 2 C 1300 1496 213 215 246 247 253 25 Y 28 X 30 Y 364 365 36 Y 500 so 50 Y 623 624 672 774 777 AA WA Inventors FREDERIC PETER HAUCK and RITA THERESA FOX ( 54) TETRAHYDRONAPHTHALENE DERIVATIVES ( 71) We, E R SQUIBB & SONS INC, a corporation organised under the laws of the State of Delaware, United States of America, residing at Lawrenceville-Princeton Road, Princeton, New Jersey, United States of America, do hereby declare the invention for which we pray that a patent may be granted to us and the method by which it is to be performed to be particularly described in and by the following statement:-
This invention relates to tetrahydronaphthalene derivatives More specifically the invention provides a compound having the formula Rs N 96 o wherein R, and R, are each hydrogen, lower alkyl or aryl.
Our copending parent patent application No 54410/76 serial No 1,564,159 describes and claims compounds of the formula 4,0 av.
which may be used in the treatment of coronary diseases As will be apparent from the following description the compounds of the present invention are intermediates useful in the preparation of compounds of formula I In formula I, and throughout the specification, the symbols are as defined below.
R 1, R and R% are the same or different and are hydrogen or acyl, with the proviso that if they are acyl, they are the same acyl group; and R is lower alkyl.
The term "acyl", as used throughout the specification, refers to groups having the formula 0 II wherein X can be a straight or branched chain alkyl group having 1 to 11 carbon atoms, an aryl group, or an aryl lower alkyl group.
Exemplary acyl groups are acetyl, propionyl, butyryl, isobutyryl, hexanoyl, heptanoyl, decanoyl, dodecanoyl, benzoyl, o toluyl, p nitro benzoyl, phenylacetyl, 3 phenylpropionyl, 3 (p chlorophenyl) butanoyl, and the like.
The term "lower alkyl" as used throughout the specification, includes both straight and branched chain alkyl groups having 1 to 4 carbon atoms.
The term "lower alkoxy", as used throughout the specification, refers to groups having the formula YO wherein Y is lower alkyl as defined above.
The term "aryl", as used throughout the specification, refers to phenyl and phenyl substituted with one or two lower alkyl, lower alkoxy, halogen, or nitro groups.
The term "aryl lower alkyl", as used throughout the specification, refers to a lower alkyl group (as defined above) substituted with an aryl group (as defined above).
The term "halogen", as used throughout the specification, refers to fluorine, chlorine, bromine, and iodine.
The compounds of formula I, and the pharmaceutically acceptable salts thereof, may be used as antifibrillatory agents and can be used to arrest cardiac arrhythmia in mammals by the inhibition of beta adrenergic receptors in the myocardium For this purpose a compound of formula I, or a pharmaceutically acceptable salt therefor, may be incorporated in a conventional dosage form such as a tablet, capsule, elixir, sterile injectable or the like, along with the necessary carrier material, ( 11) 1 564 160 1,564,160 excipient, lubricant, buffer, or the like Daily doses of from about 5 to 100 milligrams per kilogram of body weight, preferably about 5 to 10 milligrams per kilogram of body weight can be administered in single or divided doses as described above.
The compounds of formula I can be prepared using as a starting material 1,4 diacetoxy 5,8 dihydronaphthalene, ie, the compound having the formula 1,4 diacetoxy 5,8 dihydronaphthalene is a known compound, see, for example, Chem.
Ber, 62: 2345 ( 1929).
The compounds of formula I include compounds wherein the Rm O groups are in the cis and the trans configurations The configuration of the final product is determined by the initial reaction of 1,4 diacetoxy 5,8 dihydronaphthalene to yield 1,4,6,7 tetrahydroxy 5,6,7,8 tetrahydronaphthalene having the formula al Nt O trans 1,4,6,7 Tetrahydroxy 5,6,7,8 tetrahydronaphthalene can be prepared from the diacetate of formula II by dissolving the diacetate in acetic acid, and then treating the solution with from about 2 to about 4 equivalents of silver acetate and from about 1 to about 2 equivalents of iodine The mixture is then heated at a temperature of from about 80 to about 120 C for a period of from about 1 to about 24 hours under nitrogen, to yield the compound of formula III wherein the 6 and 7 hydroxy groups are in the trans configuration.
cis 1,4,6,7 Tetrahydroxy 5,6,7,8 tetrahydronaphthalene can be prepared from the diacetate of formula II by dissolving the diacetate in acetic acid and water (from 92 to 98 % acetic acid, preferably 96 % acetic acid), and then treating the solution with silver acetate and iodine and heating at a temperature of from about 80 to 120 C for a period of from about 1 to about 24 hours under nitrogen.
Prior to alkylating one of the phenolic hydroxy groups of a 1,4,6,7 tetrahydroxy 5,6,7,8 tetrahydronaphthalene of formula Im, it is necessary to first protect the adjacent hydroxy groups attached to the nonaromatic ring This can be accomplished as described in United States patent No 3,856,818 issued December 24, 1974 The resulting tetrahydronaphthalene has the formula 0// lii o H wherein R 5 and R, are each hydrogen, lower alkyl or aryl.
Alkylation of a compound of formula IV with epichlorohydrin yields a compound having the formula r The reaction can be run by forming a mixture of a block tetrahydronaphthalenediol of formula IV and epichlorohydrin in an organic solvent such as acetone and heating the mixture in an inert atmosphere While, heating, an alkali such as sodium hydroxide is added to the mixture The compounds V are the novel intermediates of the present invention.
To prepare a compound of formula I wherein R 1, R 2 and R, are each hydrogen, an oxirane compound of formula V is reacted with an alkylamine having the formula H 2 N-Rm to form an amine having the formula (VI) The reaction can be run in an organic solvent and is most conveniently run at ambient temperatures Acid hydrolysis of a compound of formula VII yields the product of formula I wherein R,, R 2 and R 3 are each hydrogen, i e, a compound having the formula o// The compounds of formula VII possess useful pharmacological activity, and can be used to arrest cardiac arrhythmia in mammals by the inhibition of beta adrenergic receptors in the myocardium.
The products of formula I wherein R,, R 2 and R 3 are each acyl can be prepared by first 1,564,160 converting an amine of formula VIII to an acid-addition salt to prevent acylation of the amino group The acid-addition salt is then acylated using conventional techniques, e g, reaction with an appropriate acid anhydride or acid chloride.
The products of formula I wherein R 1 and R? are hydrogen and R 3 is acyl can be prepared from the corresponding compound of formula VII Before proceeding with the acylation reaction it is necessary to protect the hydroxy group in the aminopropoxy side chain of the compound of formula VII Various means for protecting the hydroxy group will be apparent to the practitioner of this invention.
An exemplary method comprises reacting a compound of formula VII with an aldehyde having the formula R 7 CHO, (IX) wherein R 7 is lower alkyl or aryl, to yield an oxazolidine derivative having the formula X' The reaction can be run in an organic solvent, preferably at the reflux temperature of the solvent An oxazolidine derivative of formula X can be acylated with an acid anhydride or acid chloride to yield a compound having the formula A'g C O O \ N-R 4 ORB wherein R', is acyl Hydrolysis of a compound of formula XI yields a product of formula I wherein R, and R, are hydrogen and R% is acyl.
The products of formula I wherein R 1 is hydrogen and R 2 and R& are acyl can be prepared from a compound of formula V Reaction of a compound of formula V with a secondary amine having the formula H-NR 4 R 8 (XII) wherein R 8 is aryl lower alkyl, yields a compound having the formula The compound of formula XIII can be acylated with an acid anhydride or acid chloride to yield a compound having the formula Ay -.a-d -Cl-'-SR 4 R 9 , la wherein R'2 and R'W 3 are acyl Hydrolysis of a compound of formula XIV yields a compound having the formula O-Ad?-CY-4 t 17 VR 4 Ro Reduction of a compound of formula XV, e g, with gaseous hydrogen over a catalyst such as palladium, yields the corresponding product of formula I wherein R, is hydrogen and R.
and R, are acyl.
The compounds of formula I form acidaddition salts with inorganic and organic acids.
These acid-addition salts frequently provide useful means for isolating the products from reaction mixtures by forming the salt in a medium in which it is insoluble, and then neutralizing the salt with a base such as sodium hydroxide to obtain the free base Any other salt may then be formed from the free base and the appropriate inorganic or organic acid Illustrative are the hydrohalides, especially the hydrochloride and hydrobromide which are preferred, sulfate, nitrate, phosphate, borate, acetate, oxalate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, salicylate, methanesulfonate, benzenesulfonate, toluenesulfonate, and the like.
The following examples illustrate the preparation of compounds of Formula I and thus the use and preparation of compounds of this invention.
Example 1
8 l 3 l( 1,1 Dimethylethyl)aminol 2 hydroxypropoxyl 3 a,9 a cis 3 a,4,9,9 a tetrahydro 2,2 dimethylnaphthol 2,3 dl 1,3 dioxol 5 ol a) 1,4,6,7 Tetrahydroxy 5,6,7,8 tetrahydronaphthalene To a solution of 89 2 g of 1,4 diacetoxy 5,8 dihydronaphthalene in 1 8 liters of glacial acetic acid and 72 ml of water is added 106 6 g of silver acetate followed by 81 2 g of iodine.
The resulting slurry is then heated with stirring at 85 C+ 10 C for 3 hours under nitrogen The reaction mixture is then cooled, filtered, and the filtrate concentrated in vacuo.
To a solution of the above residue in 1 liter of methanol at O C is added a solution of g of sodium hydroxide in 800 ml of water, and the resulting mixture is stirred at room 1,564,160 temperature overnight Most of the methanol is then removed in vacuo, the resulting aqueous solution is chilled, acidified with cold concentrated hydrochloric acid, and this solution is thoroughly extracted with N butanol The combined extracts are washed with saturated aqueous sodium chloride and concentrated to near dryness in vacuo The resulting precipitate is filtered and washed well with ether to give 20 g of the title compound, melting point 221-224 C.
b) 5,8 Dihydroxy 3 a,9 a cis 3 a,4,9,9 a tetrahydro 2,2 dimethylnaphthol 2,3 dl 1,3 dioxole A slurry of 19 6 g ( 0 10 mole) of 1,4,6,7 tetrahydroxy 5,6,7,8 tetrahydronaphthalene in 250 ml of 2,2 dimethoxypropane is stirred in the presence of a trace of p toluenesulfonic acid Within 15 minutes almost all solid has dissolved After 1 hour the solution is diluted with an equal volume of ether, the resulting solution filtered through Celite (Trade Mark) to remove a small amount of suspended matter, the filtrate washed with dilute aqueous sodium bicarbonate, dried, and concentrated in vacuo to 18 g of crystalline product.
c) 8 l 2,3 (Epoxy)propoxyl 3 a,9 a cis 3 a,4,9,9 a tetrahydro 2,2 dimethylnaphthol 2,3 dl 1,3 dioxol 5 ol A stirred mixture of 18 g of 5,8 dihydroxy 3 a,9 a dcis 3 a,4,9,9 a tetrahydro 2,2 dimethylnaphthol 2,3 dl 1,3 dioxole, ml of epichlorohydrin, 60 ml of acetone and ml of water is heated to reflux under nitrogen A solution of 3 2 g of sodium hydroxide in 20 ml of water is then added over 15 minutes After the addition is complete, the mixture is refluxed for an additional 45 minutes.
The reaction mixture is then concentrated in vacuo (care is exercised to remove all excess epichlorohydrin to avoid further alkylation during base extraction), and the residue is parittioned between water and chloroform The aqueous layer is extracted with chloroform, and the combined chloroform extracts washed with saturated aqueous sodium chloride, dried, and concentrated in vacuo to yield 28 8 g of oil.
The oil is combined with a previously prepared sample 6 1 g, (total= 34 9 g), dissolved in ethyl acetate, and thoroughly extracted with cold dilute aqueous sodium hydroxide The combined aqueous extracts are chilled, acidified with cold dilute aqueous acetic acid and the resulting solution is thoroughly extracted with ethyl acetate The combined organic extracts and dried and concentrated in vacuo to 11 5 g of oil The oil is taken up in chloroform and applied to an alumina column ( 300 g, Activity III, neutral) Fractions 1-3 ( 250 ml) consist of non-polar material Fractions 3-10 ( 250 ml) give 3 1 g of the title compound after con-centration in vacua, and trituration with hexane/isopropyl ether.
d) 8 l 3 l( 1,1 Dimethylethyl)aminol 2 hydroxypropoxyl 3 a,9 a cis 3 a,4,9,9 a tetrahydro 2,2 dimethylnaphtho l 2,3 dl 1,3 dioxol 5 ol A solution of 3 1 g of 8 l 2,3 (epoxy)propoxyl 3 a,9 a cis 3 a,4,9,9 a tetrahydro 2,2 dimethylnaphtho l 2,3 dl 1,3 dioxol ol in 40 ml of absolute ethanol, 30 ml of benzene and 20 ml of t butylamine is left overnight at room temperature The solvents are removed in vacuo to yield the title compound.
Example 2 cis 4 l 3 l( 1,1 Dimethylethyl)aminol 2 hydroxypropoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, hydrochloride ( 1:1) 8 l 3 l( 1,1 Dimethylethyl)aminol 2 hydroxypropoxyl 3 a,9 a cis 3 a,4,9,9 a tetrahydro 2,2 dimethylnaphthol 2,3 dl 1,3 dioxol 5 ol, prepared above in Example 1, is dissolved in 100 ml of 5 % hydrochloric acid and left at room temperature for 1 hour.
This solution is then concentrated in vacuo to a foam This is dissolved in hot isopropanol, decolorized with Norit (Trade Mark) and diluted with ether The resulting precipitate is subjected to the same treatment to give 1 2 g of amorphous solid The amorphous material ( 1.2 g) is then recrystallized from isopropanol to give 0 30 g of crystalline solid, melting point 178-185 o C.
Example 3 cis 4 l 2 (Acetyloxy) 3 l( 1,1 dimethylethyl)aminolpropoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, triacetate ester, hydrochloride ( 1: 1) cis 4 l 3 l( 1,1 Dimethylethyl)aminol 2 hydroxypropoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol hydrochloride ( 1: 1) ( 3.62 g) is added to 50 ml of trifluoroacetic acid and the resulting solution is stirred at 0-5 C while adding 6 4 ml of acetyl chloride dropwise After the addition is completed, the solution is allowed to stand at room temperature for 1 hour The solution is then concentrated in vacuo, the residue diluted with aqueous sodium bicarbonate, and then extracted with ethyl acetate The ethyl acetate extracts are washed with saturated aqueous sodium chloride, dried, and concentrated in vacuo The residue is dissolved in dry ether, chilled, and treated with hydrogen chloride saturated isopropanol The resulting precipitate is filtered and recrystallized to yield the title compound.
Example 4 cis 4 l 3 l( 1,1 Dimethylethyl)aminol 2 hydroxypropoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, 1 acetate A solution of cis 8 l 3 l( 1,1 Dimethylethyl)aminol 2 hydroxypropoxyl 1,564,160 3 a,4,9,9 a tetrahydro 2,2 dimethylnaphthol 2,3 dl 1,3 dioxol 5 ol ( 7 31 g) and benzaldehyde ( 5 3 g) in 100 ml of xylene is refluxed for 48 hours with constant separation of water (Dean-Stark trap) The xylene and most of the excess benzaldehyde is removed in vacuo, the residue taken up in a mixture of pyridine ( 70 ml) and acetic anhydride ( 30 ml), and this solution left at room temperature for 16 hours The pyridine and excess acetic anhydride are removed in vacuo, the residue taken up in a cold ( 0 C) mixture of 225 ml of % hydrochloric acid and 25 ml of methanol, and the reaction mixture is stirred at 0-5 C for 2 hours Most of the methanol is removed in vacuo and the solution is made basic with % aqueous sodium bicarbonate and extracted with ether The combined extracts are dried over magnesium sulfate and concentrated in vacuo to yield the title compound.
Example 5 cis 4 l 2 (Acetyloxy) 3 l( 1,1 Dimethylethyl)aminolpropoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, 1 acetate A solution of 6 2 g of dcis 8 l 2,3 (epoxy)propoxyl 3 a,4,9,9 a tetrahydro 2,2 dimethylnaphthol 2,3 dl 1,3 dioxol ol in 80 ml of absolute ethanol, 60 ml of benzene, and 20 ml of benzyl t butylamine is left at room temperature for 16 hours The solution is taken to dryness in vacua, the residue taken up in 70 ml of pyridine and 30 ml of acetic anhydride, and this solution is allowed to stand at room temperature for 16 hours.
The solution is then taken to dryness in vacuo, a cold ( 6 C) mixture of 225 ml of 5 % hydrochloric acid and 25 ml of methanol is added, and the mixture is stirred at O C for 2 hours.
The solution is then made basic with 5 % aqueous sodium bicarbonate and extracted with ether The combined extracts are dried over a magnesium sulfate and concentrated in vacuo.
The above residue is dissolved in 250 ml of glacial acetic acid, one equivalent of concentrated hydrochloric acid is added, and the resulting solution is hydrogenated in the presence of 5 g of 10 % palladium/charcoal at 50-60 psi After uptake of one equivalent of hydrogen, the catalyst is filtered off and the filtrate is concentrated in vacua to yield the title compound.
Example 6
8 l 3 l( 1,1 Dimethylethyl)aminol 2 hydroxypropoxyl 3 a,9 a trans 3 a,4,9,9 a tetrahdro 2,2 dimethylnaphthol 2,3 dl 1,3 dioxol 5 ol Following the procedure of Example, 1, but substituting dry glacial acetic acid for the solution of glacial acetic acid and water in part (a), yields the title compound.
Example 7 trans 4 l 3 l( 1,1 Dimethylethyl)aminol 2 hydroxypropoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, hydrochloride ( 1: 1) Following the procedure of Example 2, but substituting 8 l 3 l( 1,1 Dimethylethyl)aminol 2 hydroxypropoxyl 3 a,9 a trans 3 a,4,9,9 a tetrahydro 2,2 dimethylnaphtho( 2,3 dl 1,3 dioxol 5 ol for its cis isomer, yields the title compound.
Example 8 trans 4 l 2 (Acetyloxy) 3 l( 1,1 dimethylethyl)aminol propoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, triacetate ester, hydrochloride ( 1: 1) Following the procedure of Example 3, but substituting trans 4 l 3 l( 1,1 dimethylethyl)aminol 2 hydroxypropoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, hydrochloride ( 1:1) for its cis isomer, yields the title compound.
Example 9 trans 4 l 3 l( 1,1 Dimethylethyl)aminol 2 hydroxypropoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, 1 acetate Following the procedure of Example 4, but substituting trans 8 l 3 l( 1,1 Dimethylethyl)aminol 2 hydroxypropoxyl 3 a,4,9,9 a tetrahydro 2,2 dimethylnaphthol 2,3 dl 1,3 dioxol 5 ol for its cis isomer yields the title compound.
Example 10 trans 4 l 2 (Acetyloxy) 3 l( 1,1 Dimethylethyl)aminolpropoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, 1 acetate Following the procedure of Example 5, but substituting trans 8 l 2,3 (epoxy)propoxyl 3 a,4,9,9 a tetrahydro 2,2 dimethylnaphtho l 2,3 dl 1,3 dioxol 5 ol for its cis isomer, yields the title compound.
Examples 11-13 Following the procedure of Example 3, but substituting the compound listed in column I for acetyl chloride, yields the compound listed in column II.
Column I 11 lauryl chloride Column II cis 4 l 3 l( 1,1 dimethylethyl)aminol 2 (lauryloxypropoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, trilaurate ester, hydrochloride Column I 12 o toluyl chloride 13 Phenylacetyl chloride 1,564,160 Column II cis 4 l 3 l( 1,1 dimethylethyl)amineol 2 (o toluyloxy)prupoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, tri(o toluate) ester, hydrochloride cis 4 l 3 l( 1,1 dimethylethyl)aminol 2 (phenylacetyloxy)propoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, tri(phenylacetate) ester, hydrochloride Examples 14-17 Following the procedure of Example 4, but substituting the compound listed in column I for acetic anhydride, yields the compound listed in column II.
Column I 14 isobutyric anhydride benzoic anhydride 16 p nitrobenzoic anhydride 17 3 (p chlorophenyl)butanoic anhydride Column II cis 4 l 3 l( 1,1 dimethylethyl)aminol 2 hydroxypropoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, 1 isobutyrate cis 4 l 3 l( 1,1 dimethylethyl)aminol 2 hydroxypropoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, 1 benzoate cis 4 l 3 l( 1,1 dimethylethyl)aminol 2 hydroxypropoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, 1 (p nitrobenzoate) cis 4 l 3 l( 1,1 dimethylethyl)aminol 2 hydroxypropoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, 1 l 3 (p chlorophenyl)butanoatel Examples 18-19 Following the procedures of Examples 1 and 2, but substituting the compound listed in column I for t butylamine, yields the compound listed in column II.
Column I 18 isopropylamine 19 methylamine

Claims (4)

WHAT WE CLAIM IS:-
1 A compound having the formula k"N wherein Rs and R,, are each hydrogen, lower alkyl or aryl.
2 A compound according to Claim 1 whereColumn II cis 4 l 2 hydroxy 3 (isopropylamino)propoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, hydrochloride cis 4 l 2 hydroxy 3 (methylamino)propoxyl 5,6,7,8 tetrahydro 1,6,7 naphthalenetriol, hydrochloride in the oxygen atoms on the tetrahydro ring are in the cis configuration.
3 A compound according to Claim 1 wherein the oxygen atoms on the tetrahydro ring are in the trans configuration.
4 A compound according to Claim 1 as named in any of the Examples.
For the Applicants, D YOUNG & CO, Chartered Patent Agents, 9 & 10 Staple Inn, London, WC 1 V 7RD.
Printed for Her Majesty's Stationery Office, by the Courier Press, Leamington Spa, 1980 Published by The Patent Office, 25 Southampton Buildings, London WC 2 A IAY from which copies may be obtained.
GB14546/79A 1976-02-09 1976-12-31 Tethrahydronaphthalene derivatives Expired GB1564160A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/656,769 US4048231A (en) 1976-02-09 1976-02-09 4-[3-(Substituted amino)-2-hydroxypropoxy]-5,6,7,8-tetrahydro-1,6,7-naphthalenetriols

Publications (1)

Publication Number Publication Date
GB1564160A true GB1564160A (en) 1980-04-02

Family

ID=24634483

Family Applications (2)

Application Number Title Priority Date Filing Date
GB14546/79A Expired GB1564160A (en) 1976-02-09 1976-12-31 Tethrahydronaphthalene derivatives
GB54410/76A Expired GB1564159A (en) 1976-02-09 1976-12-31 5,6,7,8-tetrahydronaphthalene derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB54410/76A Expired GB1564159A (en) 1976-02-09 1976-12-31 5,6,7,8-tetrahydronaphthalene derivatives

Country Status (18)

Country Link
US (2) US4048231A (en)
JP (1) JPS5943454B2 (en)
AT (1) AT349011B (en)
AU (1) AU509744B2 (en)
BE (1) BE850452A (en)
CA (1) CA1105483A (en)
CH (1) CH618676A5 (en)
DE (1) DE2701626A1 (en)
DK (1) DK51877A (en)
FR (1) FR2361335A1 (en)
GB (2) GB1564160A (en)
HU (1) HU173781B (en)
IE (1) IE45258B1 (en)
NL (1) NL7700421A (en)
NO (1) NO770415L (en)
PL (1) PL108213B1 (en)
SE (1) SE7701390L (en)
ZA (1) ZA767572B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2962112D1 (en) * 1978-02-08 1982-03-25 Ici Plc Alkanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
JPS6241829Y2 (en) * 1980-03-28 1987-10-26
FR2507181A1 (en) 1981-06-05 1982-12-10 Sanofi Sa NOVEL ETHERS OF PHENOL ACTIVE ON THE CARDIOVASCULAR SYSTEM, PROCESS FOR PREPARING THEM AND USE THEREOF IN MEDICAMENTS
CN102596889B (en) * 2009-09-11 2016-01-20 株式会社理光 Compound containing non-leaving substituent and the application in organic electronic product thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1543344A1 (en) * 1966-04-22 1969-08-07 Boehringer Sohn Ingelheim Process for the production of new 1-amino-3-aryloxypropanol-2-ethers
DE2130393C3 (en) * 1970-06-22 1981-02-26 E.R. Squibb & Sons Inc., New York, N.Y. (V.St.A.) 6,7-dihydroxy -5,6,7,8-tetrahydronaphthyloxyaminopropanols and their salts with acids and their use in combating heart disease

Also Published As

Publication number Publication date
AU509744B2 (en) 1980-05-22
GB1564159A (en) 1980-04-02
US4048231A (en) 1977-09-13
NO770415L (en) 1977-08-10
CH618676A5 (en) 1980-08-15
JPS5297953A (en) 1977-08-17
US4093814A (en) 1978-06-06
PL108213B1 (en) 1980-03-31
HU173781B (en) 1979-08-28
AT349011B (en) 1979-03-12
CA1105483A (en) 1981-07-21
IE45258B1 (en) 1982-07-28
NL7700421A (en) 1977-08-11
DK51877A (en) 1977-08-10
ATA77977A (en) 1978-08-15
DE2701626A1 (en) 1977-08-11
SE7701390L (en) 1977-08-10
FR2361335A1 (en) 1978-03-10
IE45258L (en) 1977-08-09
FR2361335B1 (en) 1980-04-30
ZA767572B (en) 1977-11-30
AU2089076A (en) 1978-06-29
BE850452A (en) 1977-07-18
JPS5943454B2 (en) 1984-10-22

Similar Documents

Publication Publication Date Title
FR2463774A1 (en) DERIVATIVES OF 2-PHENYLIMIDAZO (2,1-B) BENZOTHIAZOLE
US2820817A (en) Oxygenated indan compounds and method of making the same
NZ228614A (en) Furo (3,4-c) pyridine enantiomers; preparation by stereospecific process and therapeutic compositions
GB1564160A (en) Tethrahydronaphthalene derivatives
HU202855B (en) Process for producing new biphenyl derivatives and pharmaceutical compositions containing them as active components
HU180620B (en) Process for preparing derivatives of 2,3-indole-dione
US3637759A (en) Chromanes
Korytnyk et al. Acyl migration and selective esterification in pyridoxol
CA1146953A (en) (3-alkylamino-2-hydroxypropoxy)-furan-2- carboxylic acid anilides and physiologically tolerated acid addition salts thereof, processes for their preparation, and medicaments containing them
EP0187509A2 (en) 9-Aminoalkylfluorenes
US4569945A (en) Diarylindane-1,3-diones, their preparation and use
US4029676A (en) Esters of tetrahydronaphthyloxy-aminopropanols
JPH06504550A (en) Novel glucohydrolase inhibitors useful as antidiabetic agents
US3935236A (en) Aminopropanol substituted isochromanones and phthalides
US3933859A (en) Dihydrocoumarin derivatives
US4508735A (en) Anti-arrhythmic N-alkanoylaminoalkyl fluorenes
IE45259B1 (en) Tetrahydronaphthalene derivatives
GB1559987A (en) 1,2,3,4-tetrahydronaphthalene derivatives
EP0052238B1 (en) A new vincamine derivative, a method for its preparation and pharmaceutical compositions containing it
IE50131B1 (en) 10-bromosandwicine and 10-bromoisosandwicine processes for their preparation and their use
US2589223A (en) Hydroxy-tetrahydro-naphthoyl-alkanoic acids
FI64573B (en) FRAMEWORK FOR THERAPEUTIC USE OF THERAPEUTIC EQUIPMENT (B) BICYCLONES
US3642862A (en) Beta-(dimethylamino)ethylesters of 3-o-(carbamoyl) cassenic acids
JPS61501388A (en) organic compounds
PT93590A (en) A process for the preparation of novel 1,4-DIDESOXY-1,4-IMINO-L-ARABINITOL DERIVATIVES WITH ALPHA-GLUCOSIDASE INHIBITING ACTIVITY

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee